Skip to main content

Advertisement

SpringerLink
Log in

Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Obesity is thought to be involved in the pathogenesis of psoriasis, although its impact on the therapeutic response to systemic treatments remains unclear. The aim of this study was to examine the association of body mass index (BMI) with the efficacy of ustekinumab in Japanese patients with psoriasis. Clinical data from a cohort of 111 Japanese patients treated with ustekinumab 45 mg between July 2011 and March 2014 were retrospectively evaluated. The measured outcome was improvement in the psoriasis area and severity index (PASI) score at week 16. Patients with BMI ≥ 25 and BMI < 25 had comparable rates of ≥50 and 75 % improvement in PASI (PASI-50 and PASI-75, respectively), whereas patients with BMI ≥ 25 had significantly lower PASI-90 and PASI-100 response rates. Patients with BMI ≥ 25 also showed significantly lower percent reduction in PASI than those with BMI < 25 at week 16 (85 vs. 74 %, P < 0.004). BMI was negatively correlated with percent reduction in PASI, whereas body weight was not. These results show that a higher BMI, but not body weight, is associated with lower effectiveness of ustekinumab for psoriasis. BMI ≥ 25 could therefore be a negative predictor of achieving PASI-90 and PASI-100 in patients with psoriasis when starting ustekinumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM (2009) Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 160:670–675

    Article  CAS  PubMed  Google Scholar 

  2. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497

    Article  PubMed  Google Scholar 

  3. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88:1242–1247

    CAS  PubMed  Google Scholar 

  4. Griffiths CE, Strober BE, van de Kerkhof P et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128

    Article  CAS  PubMed  Google Scholar 

  5. Hossler EW, Wood GC, Still CD, Mowad CM, Maroon MS (2013) The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol 168:660–661

    Article  CAS  PubMed  Google Scholar 

  6. Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G (2013) Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Scand J Rheumatol 42:41–44

    Article  CAS  PubMed  Google Scholar 

  7. Igarashi A, Kato T, Kato M, Song M, Nakagawa H (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol Sci 39:242–252

    Article  CAS  Google Scholar 

  8. Jensen P, Zachariae C, Christensen R et al (2013) Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 149:795–801

    Article  PubMed  Google Scholar 

  9. Lafuente-Urrez RF, Perez-Pelegay J (2014) Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. Eur J Dermatol 24:217–223

    CAS  PubMed  Google Scholar 

  10. Lebwohl M, Yeilding N, Szapary P et al (2010) Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 63:571–579

    Article  CAS  PubMed  Google Scholar 

  11. Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674

    Article  CAS  PubMed  Google Scholar 

  12. Lindegard B (1986) Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172:298–304

    Article  CAS  PubMed  Google Scholar 

  13. Naldi L, Addis A, Chimenti S et al (2008) Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. Dermatology 217:365–373

    Article  PubMed  Google Scholar 

  14. Naldi L, Chatenoud L, Linder D et al (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125:61–67

    Article  CAS  PubMed  Google Scholar 

  15. Naldi L, Conti A, Cazzaniga S et al (2014) Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 170:634–642

    Article  CAS  PubMed  Google Scholar 

  16. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–835

    Article  PubMed  Google Scholar 

  17. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509

    Article  CAS  PubMed  Google Scholar 

  18. Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675–1684

    Article  CAS  PubMed  Google Scholar 

  19. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899–1912

    Article  CAS  PubMed  Google Scholar 

  20. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Sumarac-Dumanovic M, Stevanovic D, Ljubic A et al (2009) Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond) 33:151–156

    Article  CAS  Google Scholar 

  22. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T (2001) T lymphopaenia in relation to body mass index and TNF-α in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 54:347–354

    CAS  Google Scholar 

  23. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingard E, Stahle M (2009) Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 89:492–497

    Article  PubMed  Google Scholar 

  24. Yip SY (1984) The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 10:965–968

    Article  CAS  PubMed  Google Scholar 

  25. Zhu Y, Hu C, Lu M et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162–175

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

H. Nakagawa has received consultant and speaker fees from Janssen Pharmaceuticals K K.

Author information

Authors and Affiliations

  1. Department of Dermatology, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-Ku, Tokyo, 105-8641, Japan

    Koichi Yanaba, Yoshinori Umezawa, Toshihiro Ito, Mitsuha Hayashi, Sota Kikuchi, Osamu Fukuchi & Hidemi Nakagawa

  2. Department of Dermatology, Nippon Medical School, Bunkyo, Tokyo, Japan

    Hidehisa Saeki

Authors
  1. Koichi Yanaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshinori Umezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshihiro Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuha Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sota Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Fukuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hidehisa Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hidemi Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koichi Yanaba.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yanaba, K., Umezawa, Y., Ito, T. et al. Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients. Arch Dermatol Res 306, 921–925 (2014). https://doi.org/10.1007/s00403-014-1495-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-014-1495-1

Keywords

Search

Navigation